Potential antiproliferative effect of isoxazolo- and thiazolo coumarin derivatives on breast cancer mediated bone and lung metastases

Ballazhi, Lulzime; Popovski, Emil; Jashari, Ahmed; Imeri, Faik; Ibrahimi, Ibrahim; Mikhova, Bozhana; Mladenovska, Kristina

doi:10.1515/acph-2015-0002

Abstract

The study highlights the current progress in the development of coumarin scaffolds for drug discovery as novel anticancer agents in metastatic breast cancer. Eight compounds, combining the coumarin core and five membered heterocycles (isoxazoles and thiazoles) in hydrazinyldiene- -chroman-2,4-diones, were characterized in terms of a potential antiproliferative effect on bone (SCP1833) and lung (SCP4175) metastatic breast cancer cell lines using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay. Cell viability was evaluated after 48 and 72 h of treatment and the 50 % inhibitory concentrations were determined. The results demonstrated dose- and time-dependent activity, with the most potent molecules having a thiazole moiety, without or with additional methyl group(s) attached to the carbon(s) at position(s) 5 and/or 4 in the thiazole ring. These molecules possessed significantly higher potency against both test cell lines compared to 4-hydroxycoumarin

References

1. A. Lacy and R. O’Kennedy, Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer, Cur. Pharm. Des. 10 (2004) 3797-3811; DOI: 10.2174/1381612043382693.10.2174/1381612043382693
Search in Google Scholar
2. M. E. Marshall, M. Ryles, K. Butler and L. Weiss, Treatment of advanced renal cell carcinoma (RCC) with coumarin and cimetidine: longterm follow-up of patients treated on a phase I trial, J. Cancer Res. Clin. Oncol. 120 (1994) 535-538.
Search in Google Scholar
3. U. S. Weber, B. Steff en and C. P. Siegers, Antitumour-activities of coumarin, 7-hydroxycoumarin and its glucuronide in several human tumour cell lines, Res. Commun. Mol. Pathol. Pharmacol. 99 (1998) 193-206.
Search in Google Scholar
4. M. A. Velasco-Velazquez, J. Agramonte-Hevia, D. Barrera, A. Jimenez-Orozco, M. J. Garcia-Mondragon, N. Mendoza-Patino, A. Landa and J. Mandoki, 4-Hydroxycoumarin disorganizes the actin cytoskeleton in B16-F10 melanoma cells but not in B82 fibroblasts, decreasing their adhesion to extracellular matrix proteins and motility, Cancer Le_ . 198 (2003) 179-186; DOI: 10.1016/S0304-3835(03)00333-1.10.1016/S0304-3835(03)00333-1
Search in Google Scholar
5. S. Stanchev, G. Momekov, F. Jensen and I. Manolov, Synthesis, computational study and cytotoxic activity of new 4-hydroxycoumarin derivatives, Eur. J. Med. Chem. 43 (2008) 694-706; DOI: 10.1016/j.ejmech.2007.05.005.10.1016/j.ejmech.2007.05.005
Search in Google Scholar
6. J. L. Mohler, L. G. Gomella, E. D. Crawford, L. M. Glode, C. D. Zippe, W. R. Fair and M. E. Marshall, Phase II evaluation of coumarin (1,2-benzopyrone) in metastatic prostatic carcinoma, Prostate 20 (1992) 123-131.10.1002/pros.2990200208
Search in Google Scholar
7. F. H. Dexeus, C. J. Logothetis, A. Sella, K. Fitz, R. Amato, J. M. Reuben and N. Dozier, Phase II study of coumarin and cimetidine in patients with metastatic renal-cell carcinoma, J. Clin. Oncol. 8 (1990) 325-329.10.1200/JCO.1990.8.2.325
Search in Google Scholar
8. D. Cooke, Studies on the Mode of Action of Coumarins (Coumarin, 6-Hydroxycoumarin, 7-Hydroxycoumarin and Esculetin) at a Cellular Level, Ph. D. Thesis, Dublin City University, Dublin, 1999; h_ p:// doras.dcu.ie/18438/1/Deirdre_A_Cooke.pdf; last access date March 10, 2014.
Search in Google Scholar
9. F. Jimenez-Orozco, J. S. Lopez-Gonzalez, A. Nieto-Rodriguez, M. A. Velasco-Velazquez, J. A. Molina- Guarneros, N. Mendoza-Patino, M. J. Garica-Mondragon, P. Elizalde-Galvan, F. Leon-Cedeno and J. J. Mandoki, Decrease of cyclin D1 in the human lung adenocarcinoma cell line A-427 by 7-hydroxycoumarin, Lung Cancer 34 (2001) 185-194.10.1016/S0169-5002(01)00263-X
Search in Google Scholar
10. M. A. Musa, J. S. Cooperwood and M. O. F. Khan, A review of cumarin derivatives in pharmacotherapy of breast cancer, Cur. Med. Chem. 15 (2008) 2664-2679; DOI: 10.2174/092986708786242877.10.2174/092986708786242877377264418991629
Search in Google Scholar
11. H. A. Assi, K. E. Khoury, H. Dbouk, L. E. Khalil, T. H. Mouhieddine and N. S. El Saghir, Epidemiology and prognosis of breast cancer in young women, J. Thorac. Dis. 5 (2013) S2-S8; DOI: 10.3978/j. issn.2072-1439.2013.05.24.
Search in Google Scholar
12. Y-H. Hsiao, M-C. Chou, C. Flower, J. T. Mason and Y-G. Man, Breast cancer heterogeneity: mechanisms, proofs, and implications, J. Cancer 1 (2010) 6-13; DOI: 10.7150/jca.1.6.10.7150/jca.1.6293135420842218
Search in Google Scholar
13. Y. G. Man and H. E. Nieburgs, A subset of cell clusters with malignant features in morphologically normal and hyperplastic breast tissues, Cancer Detect. Prev. 30 (2006) 239-247; DOI: 10.1016/j. cdp.2006.04.006.
Search in Google Scholar
14. P. Clezardin, Therapeutic targets for bone metastases in breast cancer, Breast Cancer Res. 13 (2011) 207-215; DOI: 10.1186/bcr2835.10.1186/bcr2835321918121586099
Search in Google Scholar
15. M. C. Ravnan, S. L. Ravnan and M. P. Walberg, Metastatic breast cancer: a review of current and novel pharmacotherapy, Formulary 46 (2011) 130-146.
Search in Google Scholar
16. F. Cardoso, E. Senkus-Kone_ a, L. Fallowfi eld, A. Costa and M. Castigilone, Locally recurrent or metastatic breast cancer: ESMO Clinical practice guidelines for diagnosis, treatment and followup, Ann. Oncol. 21 (2010) v15-v19; DOI: 10.1093/annonc/mdq160.10.1093/annonc/mdq16020555067
Search in Google Scholar
17. O. Pagani, E. Senkus, W. Wood, M. Colleoni, T. Cufer, S. Kyriakides, A. Costa, E. P. Winer and F. Cardoso, International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J. Natl. Cancer Inst. 102 (2010) 456-463; DOI: 10.1093/jnci/djq029.18.
Search in Google Scholar
18. A. Jashari, F. Imeri, L. Ballazhi, A. Shabani, B. Mikhova, G. Drager, E. Popovski and A. Huwiler, Synthesis and cellular characterization of novel isoxazolo- and thiazolohydrazinyldiene-chroman-2,4-diones on cancer and non-cancer cell growth and death, Bioorg. Med. Chem. 22 (2014) 2655-2661; DOI: 10.1016/j.bmc.2014.03.026.19.K.
Search in Google Scholar
19. K. Tabakovic, I. Tabakovic, M. Trkovnik and N. Trinajstic, Chemistry of coumarins. Nucleophilic substitutions of 4-chloro-3-nitrocoumarin with hard and so_ nucleophiles, Liebigs Ann. Chem. 11 (1983) 1901-1909; DOI: 10.1002/jlac.198319831105.10.1002/jlac.198319831105
Search in Google Scholar
20. M. M. Ramla, M. A. Omar, A. M. M. El-Khamry and H. L. El-Diwan, Synthesis and antitumour activity of 1-substituted-2-methyl-5-nitrobenzimidazoles, Bioorg. Med. Chem. 14 (2006) 7324-7332; DOI: 10.1016/j.bmc.2006.06.033.10.1016/j.bmc.2006.06.033
Search in Google Scholar
21. E. Gulsory and N. U. Guzeldemirci, Synthesis and primary cytotoxicity evaluation of new imidazo[ 2,1-b]thiazole derivatives, Eur. J. Med. Chem. 42 (2007) 320-326; DOI: 10.1016/j.ejmech. 2006.10.012.
Search in Google Scholar
22. M. J. Choi, E. S. No, D. A. Thorat, J. W. Jang, H. Yang, J. Lee, H. Choo, S. J. Kim, C. S. Lee, S. Y. Ko, J. Lee, G. Nam and A. N. Pae, Synthesis and biological evaluation of aryloxazole derivatives as antimitotic and vascular-disrupting agents for cancer therapy, J. Med. Chem. 56 (2013) 9008-9018; DOI: 10.1021/jm400840p.10.1021/jm400840p
Search in Google Scholar
23. P. Poma, M. Notarbartolo, M. Labbozze_ a, A. Maurici, V. Carina, Alaimo, M. Rizzi, D. Simoni and N. D’Alessandro, The antitumour activities of curcumin and of its isoxazole analogue are not affected by multiple gene expression changes in an MDR model of the MCF-7 breast cancer cell line: analysis of the possible molecular basis, Int. J. Mol. Med. 20 (2007) 329-335; DOI: 10.3892/ ĳ mm.20.3.329.
Search in Google Scholar
24. M. S. Al-Said, M. S. Bashandy, S. I. Al-qasoumi and M. M. Ghorab, Anti-breast cancer activity of some novel 1,2-dihydropyridine, thiophene and thiazole derivatives, Eur. J. Med. Chem. 46 (2011) 137-141; DOI: 10.1016/j.ejmech.2010.10.024. 10.1016/j.ejmech.2010.10.024
Search in Google Scholar
25. M. I. Soares, A. F. Brito, M. Laranjo, A. M. Abrantes, M. F. Botelho, J. A. Paixao, A. M. Beja, M. R. Silva, E. Pinho and T. M. Melo, Chiral 6-hydroxymethyl-1H,3H-pyrrolo[1,2-c]thiazoles: novel antitumour DNA monoalkylating agents, Eur. J. Med. Chem. 45 (2010) 4676-4681; DOI: 10.1016/j.ejmech. 2010.07.029.
Search in Google Scholar
26. P. Chene, C. Garcia-Echeverria, M. R. Jensen, C. Quadt, T. Radimerski and J. Schoepfer, Isoxasole compound for the treatment of cancer, Patent WO 2009047323 A2, 16 April 2009.
Search in Google Scholar
27. Y. Kang, P. M. Siegel, W. Shu, M. Drobnjak, S. M. Kakonen, C. Cordon-Cardo, T. A. Guise and J. Massague, A multigenic program mediating breast cancer metastasis to bone, Cancer Cell 3 (2003) 537-549; DOI: 10.1016/S1535-6108(03)00132-6.10.1016/S1535-6108(03)00132-6
Search in Google Scholar
28. A. J. Minn, G. P. Gupta, P. M. Siegel, P. D. Bos, W. P. Shu, D. D. Giri, A. Viale, A. B. Olshen, W. L. Gerald and J. Massague, Genes that mediate breast cancer metastasis to lung, Nature 436 (2005) 518-524; DOI: 10.1038/nature03799.29.
Search in Google Scholar
29. A. Jashari, E. Hey-Hawkins, B. Mikhova, G. Draeger and E. Popovski, An improved synthesis of 4-chlorocoumarin-3-sulfonyl chloride and its reactions with diff erent bidentae nucleophiles to give pyrido[1’,2’:2,3]- and thiazino[3’,2’:2,3]-1,2,4-thiadiazino[6,5-c]Benzopyran-6-one 7,7-dioxides, Molecules 12 (2007) 2017-2028; DOI: 10.3390/12082017.10.3390/12082017614911117960102
Search in Google Scholar
30. A. Jashari, E. Popovski, B. Mikhova, R. P. Nikolova and B. L. Shivachev, 3-[2-(5-tert-butyl-1,2-oxazol-3-yl)hydrazinylidene] chroman-2,4-dione, Acta Crystalogr. E 69 (2013) o258; DOI: 10.1107/ S1600536813000858.
Search in Google Scholar

Potential antiproliferative effect of isoxazolo- and thiazolo coumarin derivatives on breast cancer mediated bone and lung metastases

Abstract

Paradigm

My account